Nocimed was created to significantly improve the diagnoses of spine pain, using technologies originally invented at the University of California at San Francisco (UCSF).
Nocimed harnesses the power of Magnetic Resonance Spectroscopy (MRS) for the non-invasive measurement of chemical biomarkers in lumbar discs, with an aim to deliver faster, more accurate diagnoses, improved treatment and greater understanding of the causes of degenerative disc disease (DDD). As of August 2019, Nocimed has earned a CE Mark to allow for sales in the EU, and registered with the FDA under the 21st Century Cures Act to allow for sales the US. In June 2019, Nocimed earned its first US revenues.